Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

apital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's therapeutic focus is oncology, but is also developing therapeutic products for inflammation, metabolic, and infectious diseases, as well as for the treatment of chronic pain. Sorrento's proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutics. In addition, Sorrento is developing proprietary Antibody Drug Conjugates as well as Antibody formulated Drug Conjugates combining its G-MAB® antibodies with anti-tumor agents.

More information is available at www.sorrentotherapeutics.com.

Forward-Looking Statements
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the preclinical and clinical development of Sorrento's human antibody therapeutics. All such forward-looking statements are based on Sor
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... N.J. , Aug. 31, 2015  ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today it has completed ... the Data Review Committee (DRC) earlier this year, ... SGX942 is a first-in-class innate defense regulator (IDR) ...
(Date:8/31/2015)... -- Premune and Innovet today ... agreement for Redonyl ® Ultra. The product, which ... dermatology market, is a nutritional supplement based on PEA-um ... dogs and cats. Redonyl ® Ultra is currently ... been received positively in the country by veterinarians and ...
(Date:8/31/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company ... for the treatment of diseases of the central nervous ... IND submission has passed review by the US Food ... Phase 1 clinical trial in patients with metastatic colon ... to 31 December 2015. Bionomics, CEO & ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... BNVI ), a pharmaceutical company focused on the ... health and cancer, today announced that Dr. Isaac Cohen, O.M.D., ... Cowen and Company 31st Annual Healthcare Conference at 9:30 a.m. ... held at the Boston Marriott Copley Place, in Boston, Massachusetts. ...
... March 7, 2011   PDL BioPharma, Inc. (PDL) ... the first quarter ending March 31, 2011 of approximately $83 ... the first quarter of 2010, an expected 34 percent year-over-year ... million settlement received from UCB Pharma S.A. (UCB) in January ...
Cached Medicine Technology:Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 3PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 4
(Date:8/31/2015)... ... August 31, 2015 , ... ... with a ribbon-cutting ceremony on Aug. 26, generously hosted by the Collinsville Chamber ... appointments via AdvantaClean’s National Call Center and website since Aug. 17. , The ...
(Date:8/31/2015)... ... 2015 , ... American Family Care (AFC), the nation’s leading ... in Tennessee with the opening of a new urgent care facility at 9203 ... in Tennessee, and 148th in the U.S. overall. , “We’re excited to continue ...
(Date:8/31/2015)... ... August 31, 2015 , ... Kognito , a ... their competencies in managing challenging conversations, announced today that Glenn Albright, Ph.D., the ... of Excellence for Psychological Health and Traumatic Brain Injury (DCoE) Summit taking ...
(Date:8/31/2015)... ... August 31, 2015 , ... In preparation for this November’s National Family ... BEAN™ personal sound amplifier, is offering caregivers “7 Reasons to Care about Hearing Health.” ... coping with a variety of home healthcare challenges, specifically as they relate to caring ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... for physicians and allied health professionals dedicated to using lifestyle as a ... the establishment of the Lifestyle Medicine Lifetime Achievement and Trailblazer Awards, with ...
Breaking Medicine News(10 mins):Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Kognito’s Glenn Albright to Present at DCoE Summit 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 3Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3
... in human cases of bird flu, causing increasing fear of ... in the scientific community to combat this impending and much ... risen since October 5 when scientists from the U.S. Army ... similarities between the bird flu strain in Asia, called H5N1, ...
... flu pandemic has created a stir worldwide with US President ... developers to speed up the process of developing a vaccine ... than 80 countries and international organizations met in Washington on ... officials including those from the World Health Organization (WHO) have ...
... Online Publication, released on the 5th of October, which ... diseases, has a comprehensive report on the threat of ... by Union Health Minister Dr Anbumani Ramadoss, the need ... challenge of chronic diseases in India was highlighted, stating ...
... Though technologic developments bring social and economic benefits ... are difficult to predict and manage. With rapid ... communications, children are increasingly exposed to EMFs at ... childhood leukemia and exposure to extremely low frequency ...
... found a new gene based test for identifying DNA fusion, ... research team is focusing on detection of genes // linked ... called as Acute Lymphoblastic Leukemia (ALL). The researchers took more ... is given by chemotherapy which kills the leukemia cells and ...
... one of life’s most distressing events, bringing in its wake ... reaction to the disease, but could have grave consequences. Because ... have an impact not only on the progression, but also ... in the ordinary course of human life, have been shown ...
Cached Medicine News:Health News:Strategies to prevent the rising tide of the epidemic of chronic diseases 2Health News:Hazards of Electromagnetic Fields for children 2Health News:Depression May Be A Risk Factor For Cancer Initiation 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: